Hiroshi Kataoka
Overview
Explore the profile of Hiroshi Kataoka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
321
Citations
4198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ushio Y, Hirata S, Manabe S, Suyama M, Tanaka A, Seki M, et al.
BMC Nephrol
. 2025 Mar;
26(1):109.
PMID: 40033218
Background: Cyanotic nephropathy (CN) is a known complication of cyanotic congenital heart disease (CCHD). However, many aspects of its pathophysiology remain unclear. Case Presentation: We report the case of a...
2.
Takeyama S, Hanaoka H, Hashimoto A, Ishii Y, Shimizu Y, Takeuchi T, et al.
BMC Rheumatol
. 2025 Feb;
9(1):25.
PMID: 40012072
Background: Pulmonary hypertension (PH) is the leading cause of death among patients with systemic sclerosis (SSc). Recently, early therapeutic intervention to improve the prognosis was suggested, and the definition of...
3.
Kataoka H, Nanaura H, Sugie K
Encephalitis
. 2025 Jan;
5(1):6-14.
PMID: 39788114
Purpose: The etiology of encephalitis is unknown in 40%-50% of cases, so a comprehensive examination of encephalitis would be significant and meaningful. The short-term outcomes in appropriately managed patients are...
4.
Kataoka H, Isogawa M, Nanaura H, Kurakami H, Hasebe M, Kinugawa K, et al.
Clin Park Relat Disord
. 2024 Dec;
11:100285.
PMID: 39650051
Introduction: Zonisamide is a medication developed in Japan that is effective for motor symptoms and wearing off in Parkinson's disease (PD). Zonisamide has properties that may improve sleep disorders. The...
5.
Imamura K, Izumi Y, Egawa N, Ayaki T, Nagai M, Nishiyama K, et al.
BMJ Open
. 2024 Oct;
14(10):e082142.
PMID: 39461864
Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive, severe neurodegenerative disease caused by motor neuron death. Development of a medicine for ALS is urgently needed, and induced pluripotent cell-based drug...
6.
Ushio Y, Yokoyama T, Manabe S, Seki M, Kawaguchi Y, Kobayashi S, et al.
Kidney Int
. 2024 Oct;
106(5):999.
PMID: 39428178
No abstract available.
7.
Kataoka H, Saeki K, Tai Y, Nanaura H, Kiriyama T, Sugie K, et al.
Parkinsonism Relat Disord
. 2024 Oct;
129:107161.
PMID: 39393315
Background: According to Japanese law, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the COVID-19 pandemic falls under Category 2, implying that it necessitates hospitalization, isolation, and significant government...
8.
Nitta K, Kataoka H, Manabe S, Makabe S, Akihisa T, Ushio Y, et al.
Clin Exp Nephrol
. 2024 Sep;
29(1):75-82.
PMID: 39322826
Background: Serum phosphate (P) levels are generally lower in autosomal dominant polycystic kidney disease (ADPKD) than in other kidney disorders, potentially masking the clinical significance of hyperphosphatemia. This study aimed...
9.
Ishizuka T, Iwadoh K, Kataoka H, Hoshino J, Nitta K, Ishida H
Antibodies (Basel)
. 2024 Aug;
13(3).
PMID: 39189233
We aimed to develop a novel method for measuring the complement-binding ability of anti-blood type antibodies (ab-Abs), the flow cytometry method for the complement C1q test (FCM-C1q) for detecting antibody-mediated...
10.
Kataoka H, Sugie K
Clin Neurol Neurosurg
. 2024 Aug;
245:108493.
PMID: 39178635
Objective: Early morning OFF (EMO) is one of the first motor complications to manifest and frequently signals the onset of additional motor complications in Parkinson's Disease (PD). Although EOM are...